Moloney Securities Asset Management’s Definium Therapeutics DFTX Stock Holding History

Moloney Securities Asset Management’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$277K	Sell	23,511 -8,000	-25%	-$74.6K	0.03%	378
2025 Q2	$205K	Sell	31,511 -4,500	-12%	-$29.6K	0.03%	438
2025 Q1	$211K	Sell	36,011 -80,500	-69%	-$577K	0.03%	423
2024 Q4	$811K	Buy	116,511 +1,000	+0.9%	+$6.88K	0.11%	203
2024 Q3	$657K	Sell	115,511 -19,800	-15%	-$138K	0.09%	246
2024 Q2	$976K	Sell	135,311 -26,650	-16%	-$233K	0.14%	161
2024 Q1	$1.52M	Buy	161,961 +92,450	+133%	+$527K	0.23%	109
2023 Q4	$254K	Buy	+69,511	New	+$209K	0.04%	358

Other funds holding DFTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Moloney Securities Asset Management's DFTX Position: Q3 2025 in Review

Moloney Securities Asset Management reduced its Definium Therapeutics (DFTX) stake by 25% in Q3 2025, selling an estimated $74.6K and leaving 23,511 shares worth $277K. The position accounts for 0.03% of the portfolio, ranked #378.

Moloney Securities Asset Management first reported a position in DFTX in Q4 2023 and has held it in 8 quarters since. The position peaked at $1.52M in Q1 2024. 195 funds tracked by Wall St. Rank hold DFTX as of Q3 2025.

Moloney Securities Asset Management held 23,511 shares of Definium Therapeutics worth $277K as of Q3 2025.
Moloney Securities Asset Management sold 8,000 Definium Therapeutics shares in Q3 2025, an estimated $74.6K.
Definium Therapeutics made up 0.03% of Moloney Securities Asset Management's portfolio in Q3 2025, its #378 holding.
Moloney Securities Asset Management first reported a position in Definium Therapeutics in Q4 2023 and has held it in 8 quarters since.
Moloney Securities Asset Management's Definium Therapeutics position peaked at $1.52M in Q1 2024.
195 funds tracked by Wall St. Rank held Definium Therapeutics as of Q3 2025.

Based on Moloney Securities Asset Management's 13F filing for Q3 2025, filed 5 Nov 2025.